Could we predict or prevent relapse after stem cell transplant?
What if we knew more about how donor lymphocyte infusion works after stem cell transplant? Does resetting and rebalancing the immune response define an immune signature and could this signature to used to predict response or relapse following stem cell transplant?
Dr Krishnamurthy will be using the fellowship to better understand why some leukaemia patients relapse following a stem cell transplant, and how donor lymphocyte infusion can help prevent this.
Play Video Stem cell transplantation is a life-saving treatment which is often the only effective treatment for acute myeloid leukaemia (AML), the most common type of acute leukaemia in adults. Yet the relapse rates following stem cell transplants are high and AML is one of the most deadly forms of blood cancer.
Dr Krishnamurthy will explore the effectiveness of a donor lymphocyte infusion (DLI) and how this may correct a patient’s immune response to help eliminate remaining leukaemic cells and prevent relapse.
This John Goldman Fellowship is co-funded by Rosetrees Trust, a charitable family foundation with a substantial track-record of funding vital medical research for over thirty years.
Read about our prestigious John Goldman Fellowships.
With blood cancer being the third biggest cancer killer in the UK, we strive to find better treatments and care to make a difference to those affected by leukaemia and other blood cancers.
We are able to fund vital research such as Dr Krishnamurthy’s project thanks to the generosity of our supporters. You can help fund our life-saving work by donating today.
Support our life-saving research by donating to Leukaemia UK.
